Voyager Therapeutics names new CEO
This article was originally published in Scrip
Interim president of R&D at Voyager Therapeutics, Dr Steven Paul, has been promoted to chief executive officer of the company. Dr Paul has been interim president since the company's launch in February 2014. Dr Paul is also a partner at venture capital firm Third Rock Ventures. He succeeds interim CEO Mark Levin, also a partner at Third Rock, who will become chair of Voyager's board of directors.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.